Physician profile
Amanda Guevara
NPI 1174357255
$1,934.12
in general payments reported to CMS, 2019-2025
15 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $121 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $650.23 | 2025 | Rezdiffra |
| Lilly USA, LLC | $288.00 | 2025 | Omvoh, Zepbound |
| Novo Nordisk INC | $193.90 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.88 | 2025 | Xifaxan |
| Janssen Biotech, INC. | $120.25 | 2025 | Tremfya |
| Qol Medical, LLC | $120.03 | 2024-2025 | Sucraid, Sucraid |
| Abbvie INC. | $98.59 | 2025 | |
| Janssen Scientific Affairs, LLC | $94.79 | 2025 | Tremfya |
| Ardelyx, INC. | $51.49 | 2025 | Ibsrela |
| Celltrion USA INC. | $50.98 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $29.17 | 2024 | |
| Braintree Laboratories, INC. | $26.85 | 2025 | Sutab, Suflave |
| Genzyme Corporation | $16.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2025 | Entyvio |
| Janssen Pharmaceuticals, INC | $9.53 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.